Forsta AP Fonden Reduces Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Forsta AP Fonden cut its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 63.1% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 25,200 shares of the biopharmaceutical company's stock after selling 43,100 shares during the quarter. Forsta AP Fonden's holdings in Alnylam Pharmaceuticals were worth $6,124,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in ALNY. Allspring Global Investments Holdings LLC increased its position in shares of Alnylam Pharmaceuticals by 572.0% in the first quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company's stock valued at $25,000 after buying an additional 143 shares in the last quarter. Ashton Thomas Private Wealth LLC purchased a new stake in shares of Alnylam Pharmaceuticals during the second quarter worth approximately $26,000. Altitude Crest Partners Inc. purchased a new stake in shares of Alnylam Pharmaceuticals during the first quarter worth approximately $30,000. Robeco Institutional Asset Management B.V. increased its position in shares of Alnylam Pharmaceuticals by 155.7% during the fourth quarter. Robeco Institutional Asset Management B.V. now owns 20,549 shares of the biopharmaceutical company's stock worth $39,000 after purchasing an additional 12,513 shares in the last quarter. Finally, V Square Quantitative Management LLC purchased a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter worth approximately $52,000. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Trading Up 1.4 %

ALNY traded up $3.54 during mid-day trading on Friday, hitting $265.27. 437,667 shares of the stock were exchanged, compared to its average volume of 894,955. The firm's fifty day moving average is $258.53 and its two-hundred day moving average is $195.09. Alnylam Pharmaceuticals, Inc. has a 1-year low of $141.98 and a 1-year high of $287.55. The company has a market cap of $34.06 billion, a PE ratio of -98.98 and a beta of 0.38.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.74) by $0.61. The firm had revenue of $659.83 million for the quarter, compared to analyst estimates of $447.22 million. During the same period in the previous year, the company posted ($2.21) EPS. Alnylam Pharmaceuticals's revenue was up 107.0% on a year-over-year basis. As a group, research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -2.73 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO Yvonne Greenstreet sold 15,000 shares of the stock in a transaction dated Tuesday, August 20th. The stock was sold at an average price of $280.00, for a total transaction of $4,200,000.00. Following the transaction, the chief executive officer now owns 73,441 shares of the company's stock, valued at approximately $20,563,480. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 15,000 shares of the company's stock in a transaction dated Tuesday, August 20th. The stock was sold at an average price of $280.00, for a total transaction of $4,200,000.00. Following the sale, the chief executive officer now owns 73,441 shares in the company, valued at approximately $20,563,480. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director David E. I. Pyott sold 32,450 shares of the company's stock in a transaction dated Monday, June 24th. The stock was sold at an average price of $220.69, for a total value of $7,161,390.50. Following the sale, the director now owns 136 shares in the company, valued at approximately $30,013.84. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 103,148 shares of company stock valued at $25,658,824. Corporate insiders own 1.50% of the company's stock.

Analyst Ratings Changes

Several analysts recently commented on ALNY shares. Morgan Stanley boosted their price target on Alnylam Pharmaceuticals from $250.00 to $255.00 and gave the stock an "equal weight" rating in a research report on Friday, July 12th. Needham & Company LLC boosted their price target on Alnylam Pharmaceuticals from $275.00 to $320.00 and gave the stock a "buy" rating in a research report on Friday, August 2nd. Leerink Partners boosted their price target on Alnylam Pharmaceuticals from $138.00 to $159.00 and gave the stock a "market perform" rating in a research report on Tuesday, June 25th. Bank of America boosted their price target on Alnylam Pharmaceuticals from $295.00 to $307.00 and gave the stock a "buy" rating in a research report on Wednesday, September 4th. Finally, Wells Fargo & Company upped their target price on Alnylam Pharmaceuticals from $207.00 to $233.00 and gave the company an "equal weight" rating in a report on Friday, August 2nd. Seven equities research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the stock. According to data from MarketBeat.com, Alnylam Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average target price of $279.14.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.